Re: The Current Stock Price does not Reflect Reality Whatsoever....
(1) Why only $4B given Erck said 150MM doses manufacturing/mo, & contractual APAs ~ $7.2 ?
(2) Why only 45-60MM doses delivered by 4/21/2022 if inventory should have been about at least 200MM doses by year-end 2021, & 450MM doses by 3/31/2022 ? Erck said back in May-2021 that on the shelf they had 30-40MM doses; would produce 50MM doses/mo thru Aug, start ramping-up higher to 100MM doses/mo sometime during 4Q, and by 1/1/2022 would be @ 150MM doses- he also revised production ruin to at least 2B doses for the 2022 production year. That only results in $4-$5B.
…..what happened maybe is the discarding of maybe up to 200MM-300MM doses; but more than likely he didn’t know what he was talking about and/or lied about that beginning inventory level and/or more likely he didn’t know or lied about what Novavax would be producing from June-2021 forward. But the better question is - given SII & SK Bio capabilities and applying Erck’s minimum 150MM/mo manufacturing- why then only the meager doses- don’t the investors and Wall Street deserve frequent updates about deliveries and manufacturing to understand the low amount of revenue relative to states production and the APAs ? This mystery and lack of any credibility is a major realm why this stock price is under $50.